Ameriprise Financial Inc Krystal Biotech, Inc. Transaction History

Ameriprise Financial Inc

$356 Billion
Q1 2025

A detailed history of Ameriprise Financial Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 60,508 shares of KRYS stock, worth $8.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,508

Previous 113,476 46.68%

Holding current value

$8.69 Million

Previous $17.8 Million 38.63%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$142.64 - $194.44 $7.56 Million - $10.3 Million	-52,968 Reduced 46.68%	60,508 $10.9 Million
Q4 2024 Feb 14, 2025	BUY	$156.64 - $199.61 $3.72 Million - $4.74 Million	23,727 Added 26.44%	113,476 $17.8 Million
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $2.14 Million - $2.62 Million	-12,247 Reduced 12.01%	89,749 $16.3 Million
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $8.97 Million - $10.8 Million	58,605 Added 135.06%	101,996 $18.7 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $2.97 Million - $4.92 Million	27,452 Added 172.23%	43,391 $7.72 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $380,160 - $508,028	3,960 Added 33.06%	15,939 $1.98 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $1.3 Million - $1.56 Million	11,979 New	11,979 $1.39 Million
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $1.09 Million - $1.4 Million	-28,806 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $481,241 - $779,760	12,996 Added 82.2%	28,806 $1.19 Million
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $553,666 - $1.04 Million	15,810 New	15,810 $684,000

Others Institutions Holding KRYS

# of Institutions

328

Shares Held

24.3M

Call Options Held

299K

Put Options Held

97.6K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.69B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Krystal Biotech, Inc. Transaction History